Empowered Patient Podcast

Karen Jagoda
  • 4,9 (18)
  • Y HỌC
  • HẰNG NGÀY

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  1. 8 GIỜ TRƯỚC · NỘI DUNG TẶNG THÊM

    New Biologic Drug for Rare IgG4-Related Disease with Dr. Adam Kilian St. Louis University School of Medicine TRANSCRIPT

    Dr. Adam Kilian, Director of the Rheumatology Fellowship Training Program at the St. Louis University School of Medicine, focuses on IgG4-related disease, a rare multi-organ disease that has only recently been recognized due to significant diagnostic challenges. The MITIGATE trial is a landmark study that demonstrated that the first FDA-approved treatment, UPLIZNA from Amgen, provides an effective, targeted, steroid-free therapy. The approval of this drug is driving awareness in the medical community about IgG4-RD and whether the disease should be considered after inconclusive results for other suspected conditions. Adam explains, "IgG4-related disease is a rare disease that affects many organ systems. It's a chronic systemic, fibroinflammatory disease that can affect almost any organ system. And it will usually present with these tumor-like inflammatory masses that can cause scarring and lead to organ failure." "Our understanding of it continues to evolve, and it's had a really interesting story over the last century because IgG4-related disease affects so many different organ systems. Over the past century, there were actually many different diagnoses that were recognized, which now all fall under the umbrella of IgG4-related disease. Different scientists and physicians around the world over the years recognized the different manifestations of the disease in the pancreas, in the lymph nodes, in the head and neck, in the kidneys, or in the blood vessels. And it's only been in the last 20 years or so that we have recognized that actually all of these different disease entities from the last century are actually all manifestations of this disease, IgG4, IgG4-related disease." "The clinical trial is called the MITIGATE trial, and it's a very seminal clinical trial in rheumatology from the last several years. This was the first-ever phase three double-blind, placebo-controlled, randomized controlled trial in IgG4-related disease. This was a huge trial. It was global. It was conducted in 22 countries with multiple specialties coordinating this trial. It was 52 weeks long, and its purpose was to evaluate the effectiveness and the safety of UPLIZNA in patients who have IgG4-related disease."  #MITIGATETrial #IgG4RelatedDisease #IgG4RD #UPLIZNA UPLIZNA Listen to the podcast here

  2. 8 GIỜ TRƯỚC

    New Biologic Drug for Rare IgG4-Related Disease with Dr. Adam Kilian St. Louis University School of Medicine

    Dr. Adam Kilian, Director of the Rheumatology Fellowship Training Program at the St. Louis University School of Medicine, focuses on IgG4-related disease, a rare multi-organ disease that has only recently been recognized due to significant diagnostic challenges. The MITIGATE trial is a landmark study that demonstrated that the first FDA-approved treatment, UPLIZNA from Amgen, provides an effective, targeted, steroid-free therapy. The approval of this drug is driving awareness in the medical community about IgG4-RD and whether the disease should be considered after inconclusive results for other suspected conditions. Adam explains, "IgG4-related disease is a rare disease that affects many organ systems. It's a chronic systemic, fibroinflammatory disease that can affect almost any organ system. And it will usually present with these tumor-like inflammatory masses that can cause scarring and lead to organ failure." "Our understanding of it continues to evolve, and it's had a really interesting story over the last century because IgG4-related disease affects so many different organ systems. Over the past century, there were actually many different diagnoses that were recognized, which now all fall under the umbrella of IgG4-related disease. Different scientists and physicians around the world over the years recognized the different manifestations of the disease in the pancreas, in the lymph nodes, in the head and neck, in the kidneys, or in the blood vessels. And it's only been in the last 20 years or so that we have recognized that actually all of these different disease entities from the last century are actually all manifestations of this disease, IgG4, IgG4-related disease." "The clinical trial is called the MITIGATE trial, and it's a very seminal clinical trial in rheumatology from the last several years. This was the first-ever phase three double-blind, placebo-controlled, randomized controlled trial in IgG4-related disease. This was a huge trial. It was global. It was conducted in 22 countries with multiple specialties coordinating this trial. It was 52 weeks long, and its purpose was to evaluate the effectiveness and the safety of UPLIZNA in patients who have IgG4-related disease."  #MITIGATETrial #IgG4RelatedDisease #IgG4RD #UPLIZNA UPLIZNA Download the transcript here

    21 phút

  3. 1 NGÀY TRƯỚC · NỘI DUNG TẶNG THÊM

    Early Detection of Alzheimer's Disease Critical to Managing the Rising Dementia Epidemic with Dr. Thomas Wisniewski NYU Langone TRANSCRIPT

    Dr. Thomas Wisniewski, Director of NYU Langone's Alzheimer's Disease Research Center, shares insights from a recent study that projects new dementia cases in the US will double by 2060. New diagnostic tools have made it easier to identify early signs of Alzheimer's, and disease-modifying therapies are being approved, which can be effective if patients are treated in the earliest stages of the disease. AI is seen as a tool to help identify at-risk patients and routinely screen patients to manage the growing need for access to dementia care.  Thomas explains, "This was a study that was led by the NY Optimal Institute, which is directed by Dr. Joe Resh, who's really a leader in this area and many public health issues. He did a very thorough analysis along with his team that the annual number of incident dementia cases in the United States is projected to increase from current estimates of 500,000 to around 1 million in 2060. So basically doubling in white adults. Furthermore, in African Americans, this incidence of dementia rate is expected to triple, with the largest absolute increases in dementia cases going to be in the oldest old population." "There was perhaps a lack of awareness of the prevalence of dementia in past decades. But now the importance of making an accurate diagnosis and recognition of dementia is becoming much more prominent in the medical literature and in the medical profession. And that message, I think, is permeating to the lay public as well. So there hasn't been a change in the definition so much, but there is an increase in knowledge in the medical profession about the importance of making this diagnosis, and people living alone." "It's really been a dramatic change. So, apart from being a cognitive neurologist, I'm also a board-certified neuropathologist, and it used to be that making the definitive diagnosis of Alzheimer's disease required a chunk of brain. I'm delighted I don't need those chunks of brain anymore to make a diagnosis of Alzheimer's disease. There are now very clear clinical criteria and biomarker definitions for making a very accurate diagnosis of Alzheimer's disease." #NYULangoneAlzheimers #AlzheimersDisease #DiagnosingAlzheimers #AlzheimersResearch #MedAI med.nyu/centers-programs/alzheimers-disease-research/ Listen to the podcast here

  4. 1 NGÀY TRƯỚC

    Early Detection of Alzheimer's Disease Critical to Managing the Rising Dementia Epidemic with Dr. Thomas Wisniewski NYU Langone

    Dr. Thomas Wisniewski, Director of NYU Langone's Alzheimer's Disease Research Center, shares insights from a recent study that projects new dementia cases in the US will double by 2060. New diagnostic tools have made it easier to identify early signs of Alzheimer's, and disease-modifying therapies are being approved, which can be effective if patients are treated in the earliest stages of the disease. AI is seen as a tool to help identify at-risk patients and routinely screen patients to manage the growing need for access to dementia care.  Thomas explains, "This was a study that was led by the NY Optimal Institute, which is directed by Dr. Joe Resh, who's really a leader in this area and many public health issues. He did a very thorough analysis along with his team that the annual number of incident dementia cases in the United States is projected to increase from current estimates of 500,000 to around 1 million in 2060. So basically doubling in white adults. Furthermore, in African Americans, this incidence of dementia rate is expected to triple, with the largest absolute increases in dementia cases going to be in the oldest old population." "There was perhaps a lack of awareness of the prevalence of dementia in past decades. But now the importance of making an accurate diagnosis and recognition of dementia is becoming much more prominent in the medical literature and in the medical profession. And that message, I think, is permeating to the lay public as well. So there hasn't been a change in the definition so much, but there is an increase in knowledge in the medical profession about the importance of making this diagnosis, and people living alone." "It's really been a dramatic change. So, apart from being a cognitive neurologist, I'm also a board-certified neuropathologist, and it used to be that making the definitive diagnosis of Alzheimer's disease required a chunk of brain. I'm delighted I don't need those chunks of brain anymore to make a diagnosis of Alzheimer's disease. There are now very clear clinical criteria and biomarker definitions for making a very accurate diagnosis of Alzheimer's disease." #NYULangoneAlzheimers #AlzheimersDisease #DiagnosingAlzheimers #AlzheimersResearch #MedAI med.nyu/centers-programs/alzheimers-disease-research/ Download the transcript here

    23 phút

  5. 4 NGÀY TRƯỚC · NỘI DUNG TẶNG THÊM

    Small Pediatric Practices Overcome Challenges of Vaccine Management with Pedro Sanchez de Lozada Canid TRANSCRIPT

    Pedro Sanchez de Lozada, CEO of Canid, highlights the significant financial risks that pediatricians face in managing their vaccine inventory.  There are administrative burdens associated with ordering, patient demand, tracking, reporting, and filing for insurance reimbursement. The Canid platform was designed to be a vaccine-as-a-service model, removing risk and administrative work from pediatric practices, allowing small and independent practices to achieve economies of scale, and freeing up more time to spend with patients and their parents.  Pedro explains, "When managing a vaccine program, the expectation is that the pediatrician will buy and maintain the stock in their office until a patient comes in and gets vaccinated. So, the refrigeration, the temperature logging, the stocking up, and the cost of the vaccine always fall as liability to the pediatrician. And what happens there is that you have a fairly small margin on these vaccines. Now I'm sure we're going to get into this, but when people say pediatricians make money on vaccines, they're usually cherry-picking." "But in reality, as a pediatrician, you actually have to stock all the vaccines. And not all of them have decent margins. Some of them have negative margins. And so as a portfolio, you end up making a pretty thin margin, and then that doesn't even include all the different challenges you might have along the way. So let's take an example: a vaccine that expires or is dropped, and unfortunately needs to be wasted."   "So the way that we like to think about it is we want to make it so that the pediatrician can just give vaccines. That's all they need to think about. And what that means is, let's just imagine for a second, a refrigerator that automatically restocks itself, and you just take out the vaccines, you give it to a child, and you go on your merry way. That's obviously a little bit of an idealistic way of viewing things, but it's the experience that we want to accomplish." #Canid #Vaccinations #Pediatricians #Vaccines #PediatricVaccineManagement   canid.io Listen to the podcast here

  6. 4 NGÀY TRƯỚC

    Small Pediatric Practices Overcome Challenges of Vaccine Management with Pedro Sanchez de Lozada Canid

    Pedro Sanchez de Lozada, CEO of Canid, highlights the significant financial risks that pediatricians face in managing their vaccine inventory.  There are administrative burdens associated with ordering, patient demand, tracking, reporting, and filing for insurance reimbursement. The Canid platform was designed to be a vaccine-as-a-service model, removing risk and administrative work from pediatric practices, allowing small and independent practices to achieve economies of scale, and freeing up more time to spend with patients and their parents.  Pedro explains, "When managing a vaccine program, the expectation is that the pediatrician will buy and maintain the stock in their office until a patient comes in and gets vaccinated. So, the refrigeration, the temperature logging, the stocking up, and the cost of the vaccine always fall as liability to the pediatrician. And what happens there is that you have a fairly small margin on these vaccines. Now I'm sure we're going to get into this, but when people say pediatricians make money on vaccines, they're usually cherry-picking." "But in reality, as a pediatrician, you actually have to stock all the vaccines. And not all of them have decent margins. Some of them have negative margins. And so as a portfolio, you end up making a pretty thin margin, and then that doesn't even include all the different challenges you might have along the way. So let's take an example: a vaccine that expires or is dropped, and unfortunately needs to be wasted."   "So the way that we like to think about it is we want to make it so that the pediatrician can just give vaccines. That's all they need to think about. And what that means is, let's just imagine for a second, a refrigerator that automatically restocks itself, and you just take out the vaccines, you give it to a child, and you go on your merry way. That's obviously a little bit of an idealistic way of viewing things, but it's the experience that we want to accomplish." #Canid #Vaccinations #Pediatricians #Vaccines #PediatricVaccineManagement   canid.io Download the transcript here

    24 phút

  7. 5 NGÀY TRƯỚC · NỘI DUNG TẶNG THÊM

    Accelerating Access to Cell and Gene Therapies with Alicia Silver ADVI Health TRANSCRIPT

    Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Listen to the podcast here

  8. 5 NGÀY TRƯỚC

    Accelerating Access to Cell and Gene Therapies with Alicia Silver ADVI Health

    Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Download the transcript here

    21 phút
Xem tất cả (2 N)

4,9
/5
18 Xếp hạng

Giới Thiệu

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Thông Tin

  • Nhà sáng tạo
    Karen Jagoda
  • Năm hoạt động
    2015 - 2025
  • Tập
    2 N
  • Xếp hạng
    Sạch
  • Bản quyền
    © 2024
  • Trang web chương trình
    Empowered Patient Podcast

Có Thể Bạn Cũng Thích